Promising Results for Neoadjuvant Immunochemotherapy in Cervical Cancer

Strategic Insights -

New research from YuceBio Technology Co. Ltd. has shown promising results for the use of neoadjuvant immunochemotherapy in treating cervical cancer. The study, which was published in the journal Signal Transduction and Targeted Therapy, aimed to evaluate the efficacy and safety of combining the anti-programmed cell death protein 1 (PD-1) antibody tislelizumab with chemotherapy in patients with stage IB3/IIA2 cervical cancer. The results suggest that this combination may be a potential option for this population.

Key Takeaways:

  • The study enrolled 30 patients with stage IB3/IIA2 cervical cancer and found that 20 (66.7%) achieved a pathological complete response (pCR) after receiving neoadjuvant immunochemotherapy.
  • The optimal pathological response rate (OPR) was 80.0%, with 17 (56.7%) complete responses and 4 (13.3%) major pathological responses (MPR).
  • The overall response rate (ORR) was 90.0%, with Grade 3 treatment-related adverse events (TRAEs) and immune-related AEs occurring in 26.7% and 3.3% of patients, respectively.
  • No treatment-related deaths occurred, and patients with pCR had significantly higher expression of PD-L1 CPS at baseline and a strong relationship with immune-related signature.
  • The study suggests that neoadjuvant tislelizumab plus chemotherapy may be a promising option for treating cervical cancer, with a well-tolerated safety profile.

Statistics:

  • 20 (66.7%) patients achieved a pathological complete response (pCR) after receiving neoadjuvant immunochemotherapy.
  • The optimal pathological response rate (OPR) was 80.0%, meaning that 80% of patients achieved a complete response or better.
  • The overall response rate (ORR) was 90.0%, meaning that 90% of patients responded to the treatment.
  • Grade 3 treatment-related adverse events (TRAEs) and immune-related AEs occurred in 26.7% and 3.3% of patients, respectively.
  • No treatment-related deaths occurred in the study.

Sources:

  • Tislelizumab (anti-PD-1) plus chemotherapy as neoadjuvant therapy for patients with stage IB3/IIA2 cervical cancer (NATIC): a prospective, single-arm, phase II study. Signal Transduction and Targeted Therapy, 2025;10(1):215.
  • Signal Transduction and Targeted Therapy can be contacted at: Springernature, Campus, 4 Crinan St, London, N1 9XW, England.